Latest Safety News

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting rare genetic diseases, supported by a strong cash position of $121 million at the end of 2025. Key clinical milestones and regulatory plans set the stage for upcoming trial readouts and potential market entry.

Structural Monitoring Systems Plc reports a profitable December quarter with 40% revenue growth, driven by strong avionics sales and progress toward FAA certification of its CVM™ technology.

MGX Resources Limited reported resilient December quarter results despite a major rockfall at Koolan Island, generating $15 million in free cashflow and advancing its acquisition of a 50% stake in the high-grade Central Tanami Gold Project.

GenusPlus Group has raised its FY2026 EBITDA guidance by approximately 35%, driven by robust half-year results and recent contract wins across its Energy & Engineering and Services segments.

Firebird Metals has advanced its manganese-rich battery materials with a patented energy-saving kiln and precursor cathode outperforming Chinese benchmarks, while planning an Australian Demonstration Plant to break into Western markets.

Hillgrove Resources met its 2025 copper production and cost guidance, boosted ore reserves by 43%, and outlined ambitious growth plans for 2026 including expanded mining at Nugent and Emily Star.

Core Lithium has unveiled an optimised mine plan for its Grants deposit that promises earlier ore production and a $35-45 million reduction in pre-production capital. The company also reported a significant increase in its Finniss Project Ore Reserve and is advancing towards a Final Investment Decision amid improved lithium market conditions.

Kingston Resources reported a 14% increase in quarterly revenue to $18.1 million despite a geotechnical setback, while underground mining development gains momentum and resource estimates grow by 29%.

Fortescue Metals Group has delivered a record first half FY26 iron ore shipment of 100.2 million tonnes, alongside key progress in decarbonisation and strategic copper acquisition.

Entropy Neurodynamics reports encouraging early clinical results from the first patient treated with TRP-8803, an IV-infused psilocin therapy for Binge Eating Disorder, showing improvements across multiple symptom areas.